TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03837236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study group
Description: Evaluation parameters will be performed to the patients. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively.
Study: NCT01939561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is tablets identically with the Lamotrigine tablets.
Study: NCT05041660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual-reality-based training
Description: Uses virtual reality for the inhibitory control training, rather than a relatively simplistic computerized training.
Study: NCT01699464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286 Ophthalmic Solution 0.7%
Description: Ophthalmic Solution
Study: NCT05041660

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Virtual-reality-based training
Description: Uses virtual reality for the inhibitory control training, rather than a relatively simplistic computerized training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhibitory Control Training
Description: Uses an active inhibitory control training which includes a stop signal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhibitory Control Training
Description: Uses an active inhibitory control training which includes a stop signal.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Inhibitory Control Training
Description: Uses an inhibitory control training which does not include a stop signal.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Inhibitory Control Training
Description: Uses an inhibitory control training which does not include a stop signal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computerized training
Description: Uses a relatively simplistic computerized training.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Computerized training
Description: Uses a relatively simplistic computerized training.
Study: NCT02870764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dan-shen extract
Description: A kind of injection made from a kind of Chinese herb: salvia miltiorrhiza

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg glugose added into 250ml 0.9% saline injection by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical care
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
Study: NCT03057067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization of pelvic vein varicosities
Description: Embolization of pelvic vein varicosities
Study: NCT02445131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Debulking: Cycles 1 - 2, d1 \& 2: 70 mg/m2 i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA101
Description: Induction: Cycle 1: d1: 100mg, d1(or2): 900mg, d8 \& 15: 1000mg; Cycle 2-6: d1: 1000mg~Maintenance: Cycle 1-8 (Duration 12 weeks): d1 1000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAL-101
Description: Induction: Cycle 2-6: d1-28: 150 mg p.o.~Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84 150 mg p.o.
Study: NCT01230099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Information Team Group
Description: A minimum of two protocolized, interdisciplinary, informational support meetings led by palliative care clinicians will be arranged with family members or other patient surrogates who participate in decision-making for individual chronically critically ill patients.
Study: NCT02001272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Carboplatin every 3 weeks
Description: Patients will receive a premedication of 130mg prednisolone the day before (22 pm) and the morning (7 am). A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel administration. At H0, Paclitaxel is administered at 175mg/m² in 3 hours then Carboplatin is administered at AUC 5mg/mL/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin monotherapy every 3 weeks
Description: A pretreatment using setrons in accordance with local standards of care will be administered 30 minutes before Carboplatin at AUC 5 to 6mg/mL/min in 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weekly Paclitaxel and Carboplatin
Description: A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel 60mg/m² in 1 hour followed by Carboplatin at AUC 2mg/mL/min in 1 hour.
Study: NCT01085084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to laquinimod will be administered per schedule specified in the arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to laquinimod will be administered per schedule specified in the arm description.
Study: NCT03904316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biodesign Otologic graft
Description: Acellular matrix derived from porcine small intestine submucosa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous temporalis fascia
Description: An autologous graft for tympanic membrane repair
Study: NCT03518411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: One-Session Unified Protocol
Study: NCT01785758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex (4 mg/Kg)
Description: Sugammadex administered at the end of surgical procedure, once skin suture had been finished, to reverse profound neuromuscular blockade induced and maintained with rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex (4 mg/Kg)
Description: Sugammadex administered at the end of surgical procedure, once skin suture had been finished, to reverse profound neuromuscular blockade induced and maintained with rocuronium
Study: NCT01699464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286 Ophthalmic Solution 0.5%
Description: Ophthalmic Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate ophthalmic solution 0.5%
Description: Ophthalmic Solution
Study: NCT04334616

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngocope
Description: VDL used for VDL arm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh Conventional Laryngocope
Description: Used for Conventional laryngocope arm
Study: NCT00476112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernakalant Injection 20 mg/mL
Study: NCT01741389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin (Circadin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin (Circadin)
Study: NCT06142981

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP and PBD-VSEL Stem Cell therapy
Description: The intervention began with the administration of three PRP sessions, where the patients received intravenous injections at four acupuncture points (stomach 36 and GB 34 on both sides) at the 1st, 2nd, and 3rd month.
Study: NCT04378647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction with Brentuximab vedotin (BV)
Description: 3 cycles ESHAP plus antibody-drug conjugate brentuximab vedotin (BV) at a dose of 1.8 mg/kg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction without Brentuximab Vedotin
Description: 3 cycles of ESHAP as a standard of care therapy for those patients with primary refractory cHL and those patients relapsing after first-line therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation with Brentuximab Vedotin
Description: Up to 13 or 16 cycles of antibody-drug conjugate brentuximab vedotin (BV) at doses of 1.8 mg/kg iv every 21 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Consolidation with Brentuximab Vedotin
Description: Up to 13 or 16 cycles of antibody-drug conjugate brentuximab vedotin (BV) at doses of 1.8 mg/kg iv every 21 days)
Study: NCT01881152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational campaign
Description: Multilevel educational campaign on stroke sympton recognition and the need for calling the Emergency Services

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Information on stroke usually delivered at the community level.
Study: NCT01662037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
Study: NCT01792388

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Capsule Form

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soya Bean oil
Description: Capsule form
Study: NCT04087564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music intervention
Description: The music intervention (Unwind), developed by the investigators collaborators at the Sync Project, is a machine learning protocol that generates specific sounds and phrases of music that are stitched into a music track in response to user-reported pain, anxiety and catastrophizing scales. Unwind is delivered via a web application on a smart phone.~Participants will also listen to white noise and their favorite music throughout the study session
Study: NCT03448705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4Fluart ID suspension for injection study drug 1 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)
Description: Route of administration: intradermal, Dosage: 1 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4Fluart ID suspension for injection study drug 2 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)
Description: Route of administration: intradermal, Dosage: 2 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3Fluart suspension for injection, influenza vaccine (whole virion, inactivated, adjuvanted)
Description: Route of administration: intramuscular, Dosage: 6 μg HA/strain / 0.5 ml, Package: 0.5 ml in one ampoule from which a total of 0.5 ml is equal to a single dose, Dosage regimen: 1 x 0.5 ml, Treatment duration: single dose.
Study: NCT04795206

Intervention type: OTHER
Intervention: No Intervention
Description: Administered as specified in the treatment arm.

Intervention type: OTHER
Intervention: No Intervention
Description: Administered as specified in the treatment arm.
Study: NCT02024659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: Patients receive 1mg/2ml budesonide twice daily via transnasal nebulization for 14 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients receive placebo (saline solution) 2ml twice daily for 14 days.
Study: NCT00721812

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1399686
Description: Safety and tolerability dose escalation in normal human volunteers

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1399686
Description: Safety and tolerability dose escalation in normal human volunteers

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1399686
Description: Safety and tolerability dose escalation in normal human volunteers
Study: NCT01083199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTINUUM™
Description: Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
Study: NCT01755546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3409
Description: Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily
Study: NCT04234945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Capsule
Description: Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamins W/Iron Tab
Description: Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding
Study: NCT04333147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Otilimab (GSK3196165)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) and auto injector (AI) to be administered SC.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Otilimab (GSK3196165)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) and auto injector (AI) to be administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: csDMARD(s)
Description: Stable dose of csDMARD(s) as standard of care (SoC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: csDMARD(s)
Description: Stable dose of csDMARD(s) as standard of care (SoC).
Study: NCT00983905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Description: single doses of 300 mg (80 mg/15 ml elixer) administered alone at 7:45 am on Day 1 and then along with colchicine at 7:45 am on Day 19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: single doses of 300 mg (80 mg/15 ml elixer) administered alone at 7:45 am on Day 1 and then along with colchicine at 7:45 am on Day 19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: one 0.6 mg tablet twice daily at 7:45 am and 7:45 pm on Days 5 to 19
Study: NCT00280683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: subjects will take matching 0.01 g/kg/day of L-arginine in divided doses for thre months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets that match the L-arginine intervention tablets will be given for three months
Study: NCT04077697

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR for influenza
Description: influenza real time polymerase chain reaction (RT-PCR) from a nasopharyngeal swab or bronchoalveolar lavage (BAL) fluid.

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR for influenza
Description: influenza real time polymerase chain reaction (RT-PCR) from a nasopharyngeal swab or bronchoalveolar lavage (BAL) fluid.
Study: NCT01169636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Starting Day -6 of Cycle 1, 20 mg orally on Monday, Wednesday, and Friday during Cycles 1 and 2 (Days -6, -4, and -2 of Cycle 1 and Days 1, 3, 5, 8, 10, and 12 of Cycles 1 and 2); MTD found in Phase 1 used for same schedule in Phase 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Starting Day -6 of Cycle 1, 20 mg orally on Monday, Wednesday, and Friday during Cycles 1 and 2 (Days -6, -4, and -2 of Cycle 1 and Days 1, 3, 5, 8, 10, and 12 of Cycles 1 and 2); MTD found in Phase 1 used for same schedule in Phase 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Day 1 of Cycles 1-3, 5 grams/m2 by vein over 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Day 1 of Cycles 1-3, 5 grams/m2 by vein over 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Day 1 of Cycles 1-3, 5 grams/m2 by vein over 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: On Day 1 of Cycles 1-3, 2 grams/m2 by vein over 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: On Day 1 of Cycles 1-3, 2 grams/m2 by vein over 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: On Day 1 of Cycles 1-3, 2 grams/m2 by vein over 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: On Day 1 of Cycles 1-3, Standard Dose (Target area under curve (AUC) = 5mg/ml/min) by vein over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: On Day 1 of Cycles 1-3, Standard Dose (Target area under curve (AUC) = 5mg/ml/min) by vein over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: On Day 1 of Cycles 1-3, Standard Dose (Target area under curve (AUC) = 5mg/ml/min) by vein over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: On Days 1-3 of Cycles 1-3, 100 mg/m2 by vein over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: On Days 1-3 of Cycles 1-3, 100 mg/m2 by vein over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: On Days 1-3 of Cycles 1-3, 100 mg/m2 by vein over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Beginning Day 4 of Cycles 1-3, 6 mg under the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Beginning Day 4 of Cycles 1-3, 6 mg under the skin.
Study: NCT03088098

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LAAO
Description: Left atrial appendage occlusion for stroke prevention
Study: NCT00632385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan
Description: 40 mg oral tablet for migraine attack, followed by 40 mg oral tablet if migraine reoccurred \>2 hours from first dose and within 24 hours of first dose
Study: NCT02743299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handivent Ventilator
Description: CPR with use of a turbine-driven ventilator (Handivent)
Study: NCT04366362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualised ACL reconstruction
Description: ACL reconstruction based on anatomical and functional distinctiveness of each patient separately

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ACL reconstruction
Description: ACL reconstruction based on surgeons experience without taking into account any other patients characteristics
Study: NCT03660397

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective endovascular chemical ablation of adrenal gland
Description: Intervention with selective endovascular chemical ablation of adrenal gland is performed after adrenal angiography in the group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional triple antihypertensive treatment
Description: irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional triple antihypertensive treatment
Description: irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
Study: NCT03423368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Libramed
Description: Policaptil Gel Retard

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-comparator
Study: NCT00883636

Intervention type: OTHER
Intervention: Cardiovascular Assessment
Description: Measure of BNP, and Pro-BNP Complete 2 Dimensional Echocardiogram with Doppler evaluation including determination of, Left Ventricular mass, Ejection fraction, Midwall fractional shortening, velocity of early and late diastolic transmitral flow, and measurement of E/A ratio, Ratio of end-systolic wall stress to rate corrected velocity of circumferential fiber shortening.

Intervention type: OTHER
Intervention: Cardiovascular Assessment
Description: Measure of BNP, and Pro-BNP Complete 2 Dimensional Echocardiogram with Doppler evaluation including determination of, Left Ventricular mass, Ejection fraction, Midwall fractional shortening, velocity of early and late diastolic transmitral flow, and measurement of E/A ratio, Ratio of end-systolic wall stress to rate corrected velocity of circumferential fiber shortening.

Intervention type: OTHER
Intervention: Renal Assessment
Description: Complete a metabolic panel, CMP. Calculation of glomerular filtration rate, GFR, measure of urinary total protein, albumin and creatinine excretion in a first morning urine sample, 24 hour blood pressure monitoring,

Intervention type: OTHER
Intervention: Renal Assessment
Description: Complete a metabolic panel, CMP. Calculation of glomerular filtration rate, GFR, measure of urinary total protein, albumin and creatinine excretion in a first morning urine sample, 24 hour blood pressure monitoring,

Intervention type: OTHER
Intervention: Genetic Evaluation
Description: All patients will undergo genetic screening for all known podocyte gene mutations.

Intervention type: OTHER
Intervention: Genetic Evaluation
Description: All patients will undergo genetic screening for all known podocyte gene mutations.
Study: NCT03419676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: Collagen patch derived from bovine dermis, coated with NHS-PEG, applied covering the pancreaticojejunostomy after pancreatoduodenectomy once the anastomosis is completed.
Study: NCT02579824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3032b
Description: Escalation DS-3032b starting dose level 90 mg/day administered once daily by mouth on Days 1 - 21 of a 28 day cycle. For Dose Expansion maximum tolerated dose from Dose Escalation Phase.